Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501 and ALLO-501A at the ASCO Annual Meeting from June 2-6, 2023. These trials assess the safety and preliminary efficacy of the allogeneic CAR T cell products targeting CD19. Allogene is also enrolling patients in the Phase 2 ALPHA2 trial for large B cell lymphoma (LBCL). The data presentation will feature results that highlight the potential of ALLO-501 and ALLO-501A to induce durable responses in relapsed/refractory LBCL. The FDA has granted ALLO-501A RMAT designation, indicating its potential for expedited development. Allogene aims to set a new standard in CAR T therapies.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology firm, will report its first quarter 2023 financial results on May 3, 2023, after market close. A conference call will follow at 2 PM PT/5 PM ET, allowing participants the chance to engage. The company focuses on developing allogeneic CAR T products for cancer treatment. They aim to provide reliable, readily available cell therapies at a larger scale.

This announcement emphasizes Allogene's commitment to advancing innovative cancer therapies. The call will be open to the public via a listen-only webcast available on the company's website. The forward-looking statements within the release indicate the uncertainty surrounding future product development, with risks outlined in their SEC filings.

Allogene Therapeutics (Nasdaq: ALLO) has appointed Timothy Moore as Executive Vice President and Chief Technical Officer, effective April 24, 2023. Moore, a former executive at Kite Pharma, is recognized for leading the successful manufacturing processes behind two top autologous CAR T therapies. His experience is expected to bolster Allogene's aim of being first to market with an allogeneic CAR T product. Timothy Moore succeeds Alison Moore, Ph.D., who will transition to a consulting role.

Moore brings over 30 years of expertise in biopharmaceutical manufacturing and operations, having played a key role in the development of Yescarta and Tecartus. His appointment comes as Allogene prepares for a potential regulatory submission for its allogeneic CAR T products, reflecting the company's commitment to advancing innovative cancer therapies.

Allogene Therapeutics (NASDAQ: ALLO) presented interim results from its Phase 1 TRAVERSE trial for ALLO-316, a CAR T candidate targeting CD70 in renal cell carcinoma (RCC), at the AACR Annual Meeting on April 17, 2023. The trial enrolled 19 patients, with 10 exhibiting CD70 expression. Notably, three of those patients achieved a partial response, contributing to a 100% disease control rate among CD70+ patients. ALLO-316 utilizes proprietary Dagger™ technology to enhance cell expansion and persistence while resisting rejection. As of March 23, 2023, the trial has shown early signs of tumor activity, with further dose escalation ongoing. The overall disease control rate across all patients reached 89%. Initial safety results indicated a manageable adverse event profile, with no instances of ICANS or graft-versus-host disease reported.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) has announced its participation in four upcoming investor conferences. These events include:

• Canaccord Genuity - CG Horizons in Oncology Virtual on April 20, 2023, at 8:00 AM PT
• BofA Securities 2023 Health Care Conference on May 10, 2023, at 4:20 PM PT
• The JMP Securities Life Sciences Conference on May 15, 2023, at 8:30 AM PT
• 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023, at 1:35 PM PT

Webcasts of these events will be available on the company’s website under the Investors tab. Allogene Therapeutics focuses on developing allogeneic CAR T products aimed at improving cancer treatment, striving to provide 'off-the-shelf' therapies for patients.

Allogene Therapeutics (Nasdaq: ALLO) announced interim data from its Phase 1 TRAVERSE trial for ALLO-316, targeting renal cell carcinoma (RCC) patients who previously received immune therapies. The results will be presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2023. Initial data show ALLO-316 exhibits antitumor activity and utilizes Dagger™ technology to mitigate immune rejection. The U.S. FDA granted Fast Track Designation to ALLO-316 in March 2022, highlighting its potential for treating difficult RCC cases. The ongoing trial will assess safety, tolerability, and effectiveness while exploring patient selection through a new diagnostic assay.